DR. MELISSA KAY THOMAS, MD PHD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 161282
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
112 Eo112 SUITE NEUROENDOCRINE, Boston, MA 02114
Phone
(617) 726-7948
(617) 726-1241 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
(617) 726-1241 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
Personal information
See more information about MELISSA KAY THOMAS at radaris.comName
Address
Phone
47 Juniper Rd UNIT E11, North Attleboro, MA 02760
44 Guild St #1, Roxbury, MA 02119
44 Guild St, Roxbury, MA 02119
44 Washington St APT 201, Brookline, MA 02445
Professional information
See more information about MELISSA KAY THOMAS at trustoria.com
Gift Manager At The Paper Store
Gift Manager At The Paper Store
Position:
Gift Manager at The Paper Store
Location:
Greater Boston Area
Industry:
Retail
Work:
The Paper Store
- Dedham, MA since Aug 2011
-
Gift Manager
Event Network
Jul 2010 - Aug 2011
-
Assistant Store Director
The Disney Store
Oct 2005 - Jul 2010
-
Assistant Store Manager
The Disney Store
Jul 2005 - Oct 2005
-
Lead Castmember
The Disney Store
Jun 2000 - Jun 2005
-
Castmember
Citizens Bank
Jun 2002 - Dec 2004
-
Senior Teller
Medford Savings Bank
Jul 2001 - Jun 2002
-
Teller
Education:
University of Massachusetts at Lowell 1998 - 2002
BA, English
BA, English
Director Integrated Supply Chain - Raytheon
Director Integrated Supply Chain - Raytheon
Position:
Integrated Supply Chain at Raytheon
Location:
Greater Boston Area
Industry:
Defense & Space
Work:
Raytheon
since Sep 2005
-
Integrated Supply Chain
Invensys
Jan 1999 - Sep 2005
-
Director Electronics Supply Chain
Education:
Clarkson University 1984 - 1987
B.S., Industrial Engineering
B.S., Industrial Engineering
Account Manager At Netria Corporation
Account Manager At Netria Corporation
Position:
Account Manager at Netria Corporation
Location:
Greater Boston Area
Industry:
Computer Hardware
Work:
Netria Corporation
-
Account Manager
Owner At Melissa M Thomas Cpa
Owner At Melissa M Thomas Cpa
Position:
owner at Melissa M Thomas CPA
Location:
Greater Boston Area
Industry:
Accounting
Work:
Melissa M Thomas CPA
-
owner
Method Of Pre-Inducing A State Of Immune Tolerance Before Organ Transplantation
Method Of Pre-Inducing A State Of Immune Tolerance Before Organ Transplantation
US Patent:
6923959, Aug 2, 2005
Filed:
May 2, 2002
Appl. No.:
10/136891
Inventors:
Joel F. Habener - Newton Centre MA, US
Henryk Zulewski - Basel, CH
Elizabeth J. Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Denise L. Faustman - Weston MA, US
Melissa K. Thomas - Boston MA, US
Henryk Zulewski - Basel, CH
Elizabeth J. Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Denise L. Faustman - Weston MA, US
Melissa K. Thomas - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K035/12, C12N005/00
US Classification:
424 937, 424 931, 424520, 435 11, 435 4, 435325
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
US Patent:
2003008, May 1, 2003
Filed:
Apr 11, 2002
Appl. No.:
10/120687
Inventors:
Joel Habener - Newton Centre MA, US
Henryk Zulewski - Basel, CH
Melissa Thomas - Boston MA, US
Elizabeth Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Colin Leech - Boston MA, US
Anna Nolan - Brookline MA, US
Andreas Lechner - Boston MA, US
Henryk Zulewski - Basel, CH
Melissa Thomas - Boston MA, US
Elizabeth Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Colin Leech - Boston MA, US
Anna Nolan - Brookline MA, US
Andreas Lechner - Boston MA, US
International Classification:
A61K048/00, C12N005/08
US Classification:
424/093210, 435/366000
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
US Patent:
7544510, Jun 9, 2009
Filed:
Apr 24, 2006
Appl. No.:
11/410412
Inventors:
Joel F. Habener - Newton Centre MA, US
Elizabeth J. Abraham - Andover MA, US
Henryk Zulewski - Binningen, CH
Melissa K. Thomas - Boston MA, US
Mario Vallejo - Madrid, ES
Elizabeth J. Abraham - Andover MA, US
Henryk Zulewski - Binningen, CH
Melissa K. Thomas - Boston MA, US
Mario Vallejo - Madrid, ES
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
C12N 5/00, C12N 5/06
US Classification:
435325, 435395, 435402
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
US Patent:
2003005, Mar 20, 2003
Filed:
Apr 3, 2002
Appl. No.:
10/115515
Inventors:
Joseph Beavo - Seattle WA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Seattle WA, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Mountlake Terrace WA, US
Melissa Thomas - Boston MA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Seattle WA, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Mountlake Terrace WA, US
Melissa Thomas - Boston MA, US
Assignee:
ICOS Corporation
International Classification:
A61K038/17, C07H021/04, C12N009/20, C12P021/02, C12N005/06
US Classification:
514/012000, 435/198000, 435/069100, 435/325000, 435/320100, 536/023200
Abstract:
The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.
Methods To Stimulate Insulin Production By Pancreatic Beta-Cells
Methods To Stimulate Insulin Production By Pancreatic Beta-Cells
US Patent:
6903073, Jun 7, 2005
Filed:
Dec 8, 2000
Appl. No.:
09/733634
Inventors:
Joel F. Habener - Newton Centre MA, US
Melissa K. Thomas - Boston MA, US
Melissa K. Thomas - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K038/00
US Classification:
514 12, 514 2, 530300, 530325
Abstract:
The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
US Patent:
2005019, Sep 8, 2005
Filed:
Jan 28, 2003
Appl. No.:
10/353575
Inventors:
Joseph Beavo - Seattle WA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Madison CT, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Spring TX, US
Melissa Thomas - Boston MA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Madison CT, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Spring TX, US
Melissa Thomas - Boston MA, US
International Classification:
C12N009/16, C07H021/04, A61K031/519
US Classification:
435069100, 435196000, 435320100, 435325000, 514252160, 536023200
Abstract:
The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding. cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.